Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Progressive disseminated histoplasmosis in the HIV population in Europe in the HAART era. Case report and literature review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Causes of death among Danish HIV patients compared with population controls in the period 1995-2008

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Bacteremia in connection with transurethral resection of the prostate.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

Vis graf over relationer

ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥ 3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.

Udgave nummer4
Sider (fra-til)757-62
Antal sider6
StatusUdgivet - aug. 2014

ID: 44664371